AI

FDA authorizes software to identify prostate cancer

The U.S. Food and Drug Administration authorized marketing of software to assist medical professionals who examine body tissues (pathologists) in the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue removed from the body).

The software, called Paige Prostate, is the first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.

“Pathologists examine biopsies of tissue suspected for diseases, such as prostate cancer, every day. Identifying areas of concern on the biopsy image can help pathologists make a diagnosis that informs the appropriate treatment,” said Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health. “The authorization of this AI-based software can help increase the number of identified prostate biopsy samples with cancerous tissue, which can ultimately save lives.”

The FDA reviewed the device through the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this authorization, the FDA is establishing special controls for devices of this type, including requirements related to labeling and performance testing. When met, the special controls, along with general controls, provide reasonable assurance of safety and effectiveness for devices of this type. This action creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through FDA’s 510(k) premarket process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.

The FDA granted marketing authorization of the Paige Prostate software to Paige.AI.

23.09.2021

Read all latest stories

Related articles

Photo

News • New method

3D imaging to determine prostate cancer aggressiveness

A team led by the University of Washington has developed a new, non-destructive method that images entire 3D biopsies instead of a slice. The 3D images provided more information than a 2D image —…

Photo

News • Prostate cancer

Diagnosing cancer using a urine test with AI

Prostate cancer is one of the most common cancers among men. Patients are determined to have prostate cancer primarily based on PSA, a cancer factor in blood. However, as diagnostic accuracy is as…

Photo

News • The 'PodoSighter'

AI identifies key indicator of early kidney disease

Researchers have leveraged the power of digital pathology and computational modeling to detect and quantify podocytes, a specialized type of cell in the kidney that undergoes damaging changes during…

Related products

Image Information Systems – iQ-View

Reading

Image Information Systems – iQ-View

IMAGE Information Systems Europe GmbH
Agfa HealthCare – Rubee for AI

Artificial Intelligence

Agfa HealthCare – Rubee for AI

Agfa HealthCare
Canon – Advanced intelligent Clear-IQ Engine for MR

Artificial Intelligence

Canon – Advanced intelligent Clear-IQ Engine for MR

Canon Medical Systems Europe B.V.
Canon - Aquilion Exceed LB

Oncology CT

Canon - Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Canon – Aquilion Lightning

20 to 64 Slices

Canon – Aquilion Lightning

Canon Medical Systems Europe B.V.
Canon – Aquilion Lightning SP

Volume CT

Canon – Aquilion Lightning SP

Canon Medical Systems Europe B.V.
Subscribe to Newsletter